Biomarkers Market Analysis Outlook 2017- 2025: Size, Cost Structures, Growth Rate
The Biomarkers Market Is Estimated To Be Valued At US$ 29,518.2 Mn In 2017 And Is Expected To Witness A Robust CAGR Of 13.6% During The Forecast Period (2017-2025).
Biomarkers Market |
Because they can distinguish between normal and abnormal bodily processes, biomarkers are the molecules that are utilised to diagnose diseases. Any molecule, including DNA (genes), proteins, or hormones, can serve as a biomarker. They can be categorised based on a variety of factors, including features like imaging or molecular biomarkers. The need for biomarkers is growing in the drug research and development process since using them improves patient outcomes, lowers costs, and raises the success rate of drug development. More quickly than traditional clinical endpoints, biomarkers also help in predicting therapeutic efficacy.
The need for biomarkers is increasing
as a result of the increasing use of biomarkers in the creation of new products
and the treatment of chromosome-related illnesses such as Turner syndrome, Down
syndrome, Patau syndrome, Edwards' syndrome, and others. For instance, Banyan
Biomarkers, Inc. received marketing approval from the FDA in February 2018 for
Banyan BTI, the first diagnostic blood test for traumatic brain injury.
Therefore, it is anticipated that the introduction of such cutting-edge
diagnostic techniques for a range of illness indications will spur growth of
the Biomarkers
Market during the
course of the forecast year.
Pharmaceutical firms have started
contracting out difficult bio analyses not only to save costs but also to gain
access to specialist knowledge and increase productivity in the drug
development process. For instance, in March 2018, SenzaGen and Burlesson
Research Technologies, Inc. (BRT), a contract research firm in the United
States that specialises in immunotoxicology, signed a crucial licence deal.
This partnership will make BRTs' "GARD" available to a larger market.
A collection of tests known as GARD are used to evaluate chemical sensitizers.
These tests include genetic biomarkers for more than 200 genes, which encompass
the complete immune response and are important for predicting the likelihood of
hypersensitivity. In the near future, the Biomarkers
Market is anticipated to increase favourably as a result of such improvement
and innovation by CROs.
A key driver of Biomarkers Market expansion is
anticipated to be the rising use and awareness of biomarker tests. Instead of
using traditional diagnostic techniques, biomarkers are used for early disease
detection and diagnosis. Additionally, biomarkers like BRCA1 show whether a
person has a higher risk of acquiring cancer. Additionally, biomarkers are used
in a wide range of therapeutic fields, such as oncology, metabolic disorders,
immunological dysregulation, and neurological diseases to treat conditions as
TMI, cancer, and Alzheimer's diagnosis. ABO newborn hemolytic disorder,
Huntington disease, hereditary hemochromatosis, and cystic fibrosis are further
conditions for which biomarkers are used.
Comments
Post a Comment